cifenline succinate
Small moleculeexperimental
Cibenzoline is a Class Ia antiarrhythmic. — Wikipedia
Clinical trial activity
1 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Aug 1, 2003 (NCT00540787)
Timeline
No events for the selected filters.
Indications
Approved for
Studied for
Mechanism of action
Chemistry & pharmacology
Loading structure…
SMILES
c1ccc(C2(c3ccccc3)CC2C2=NCCN2)cc1- Mol. weight
- 262.36 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- Yes
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL87045 ↗
- WikipediaCibenzoline ↗
- ChEMBLCHEMBL2106074 ↗
Also known as
- 2-(2,2-diphenylcyclopropyl)-2-imidazoline
- cibenzoline
- cibenzoline
- cibenzoline
- cibenzoline
- cibenzoline
- (+/-)-cibenzoline
- cibenzoline succinate
- cibenzoline succinate
- cifenline
- cifenline
- cifenline
- cifenline
- cifenline
- cifenline, (s)-isomer
- cifenline succinate
- cifenline succinate
- cipralan
- exacor
- (rs)-cibenzoline
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00540787 | Phase 4 | Aug 1, 2003 | Biosense Webster, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Biosense Webster, Inc. | For profit | 1 | 1 | 1 | 2003 |
1 organizations
Page 1 / 1